In The Spotlight
DDNews Cancer Research Exclusive
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
(Photo credit: University of Toronto)
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
The Patient-Centered Outcomes Research Institute (PCORI) board of governors will be awarding $97.9 million to fund 11 studies that will compare different approaches to improving care for several health conditions
Esanex presents new data on SNX-5422 at international cancer conference
Bio-Path Holdings Inc. has selected its third drug candidate, BP1003, for the treatment of pancreatic cancer
Five Prime Therapeutics Inc. presented at the recent 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, sharing new preclinical data that demonstrate the potent antitumor activity of FPT155, its novel therapeutic CD80-Fc fusion protein
An old relationship is getting a boost as Cellectar Biosciences Inc. and Pierre Fabre extend their existing collaboration to develop phospholipid drug conjugates
Mount Sinai team reports success in using mathematical model to predict patient response to immunotherapy
Boehringer Ingelheim and Sarah Cannon Research Institute broaden work into immuno-oncology
Featuring "Oncology vs. the supervillains," an article looking at several companies' recent news related to tackling some of the toughest cancers, plus a roundup of other cancer research news recently
(Photo credit: NCI, NIH)
The latest Annual Report to the Nation shares that cancer survival rates are rising, while incidence and death rates are on a downward trend
by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors

by Dr. Brad Thompson, Oncolytics
During these heady and still-early days in the age of clinical studies involving immunotherapy, it is useful to ponder some of the outstanding questions these studies raise

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.